Melnychuk et al. showed in their analysis that patients with CAD had higher levels of apoB compared to the control group, yet apoB was not the main biomarker evaluated, and the study did not include QCA lesion quantification or specific information about CAD burden [46]. This evidence concerns the gene APOB and coronary artery disorder.